Compass Pathways announces that Kabir Nath will replace George Goldsmith as CEO effective August 1, 2022.

Better Life Pharma announces additional funding to study BETR-001 as a treatment for depression, via the Mitacs Accelerate program.

Red Light Holland announces a partnership with platinum-selling rapper, Wiz Khalifa, to launch Red Light Holland’s MISTERCAP brand of psilocybin-based products.

Cybin Inc reports its fiscal year 2022 financial results, including progress on several pipeline initiatives, with a cash balance of CAD$53.6 million as of March 31, 2022.

Numinus announces a pilot program to encourage employers to offer ketamine-assisted psychotherapy to employees as a health benefit.

Better Life Pharma will be presenting an abstract on its lead compound, BETR-001, to the European Neuroscience Societies (FENS) Forum in July.

Numinus Wellness announces the completion of its acquisition of Novamind Inc, with Novamind shareholders receiving 0.84 shares of Numinus per Novamind share.

Cybin Inc announces acquiring a Phase 1 DMT study from Entheon Biomedical, at a purchase price of CAD$1 million plus additional considerations.

Cybin announces publication of EMBARK, a model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing.

Novamind Inc reports its Q3 for fiscal 2022. Quarterly revenues of CAD$3,227,352 represent a q-o-q of 32%. Novamind also expanded into the Arizona market in Q2 with its clinic operations.